1. Scrip
  2. >>Business
  3. >>Deals

Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement

Japanese Pharma Trades 50-50 Deal For Single-Digit Royalty

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.

Close-up Of A Businessperson Passing Baton
Eisai passed full Aduhelm decision-making authority to Biogen • Source: Alamy

It appears that Eisai Co., Ltd. is throwing in the towel on the troubled anti-amyloid antibody Aduhelm (aducanumab), giving Biogen, Inc. full control of decision-making for the Alzheimer’s disease therapy, effective immediately. The companies will continue to share Aduhelm profits and losses globally in 2022 – with Eisai’s development, commercialization and manufacturing costs capped at $335m this year – but the Japanese company will no longer fund those costs beyond 2022 and from 2023 onward will collect only a single-digit percentage royalty on Aduhelm sales worldwide.

Eisai’s tiered royalty will start at 2% and could rise as high as 8% under the amended agreement if annual...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.